New Hot Flash Drug Hits NHS + The Menopause Marketing Explosion
This episode covers the NHS approval of fezolinetant, a new non-hormone drug for hot flashes, the concerning surge in menopause product marketing, and breakthrough research on how menopause changes brain structure and function. Nykki discusses both the promise and pitfalls of the current menopause treatment landscape. Key Takeaways: • Fezolinetant, a new non-hormone drug that blocks neurokinin 3 receptors, is now available on NHS and can reduce hot flash frequency by about half • The menopause product market is projected to reach $24 billion by 2030, but many products lack rigorous clinical…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.